European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019)

URI dla tej Kolekcjihttp://repozytorium.ur.edu.pl/handle/item/4512

Przeglądaj

Aktualnie wyświetlane 1 - 4 z 4

Efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in patients with active fistulizing perianal Crohn’s disease naďve to anti-TNF therapy: preliminary results from the POLIBD study
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Pękala, Anna; Aebisher, David; Pardak, Piotr; Filip, Rafał
Introduction. The development of perianal fistulas are a risk factor in colonic and rectal disease. Perianal CD treatment requires a combination of surgical and therapeutic treatments aimed to prevent septic complications, reduce fistula discharge and ultimately heal fistulas. Aim. The purpose of the study was to evaluate the efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in active fistulizing perianal Crohn’s disease (CD) in patients from the Subcarpathian Region (South-Eastern Poland). Material and methods. Thirty patients with CD with perianal fistulas naive to anti-TNF therapy were enrolled (13 females/ 17males) ranging from 18 to 64 years of age. Twenty-one were treated with biosimilar infliximab (CT-P13), nine were treated with adalimumab (ADA). The treated patients had ileal CD (4), ileo-colonic CD (13) or colonic CD (13). All of them received standard immunosuppression with no additional steroid therapy. Response was evaluated at week 16 and 40 after the first CT-P13 dose, and 16 and 40 weeks after the first ADA dose. Remission was defined as the complete closure of all fistulas and partial response as a reduction (≥50%) in the number of draining fistulas. Results. Treatment outcomes with CT-P13 and ADA were both effective and similar in the percentage of patients with perianal fistula improvement, perianal fistula remission, no effect or observed adverse events. Conclusion. In patients with active fistulizing CD, both CT-P13 and ADA were effective and safe, however a slight superiority of CT-P13 was visible.
Infliximab in therapy of inflammatory bowels diseases
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bar, Piotr; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, David
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.
Infliximab MRI relaxation time in solution
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bober, Zuzanna; Bar, Piotr; Pasternak, Grzegorz; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, David
Introduction. The use of Quantitative Magnetic Resonance Imaging to drug monitoring in vitro or in vivo can provides a powerful means to map the effects of drugs on tissue activity. Aim. The purpose of this study was to measure relaxation time of antibody phantom. For this purpose, infliximab sample was used. Material and methods. The selected methods to detect relaxation time of antibody was Magnetic Resonance Imaging technique. We detected spin-lattice (T1) relaxation time and discuss differences where compare to water. Results. The measurements of spin-lattice (T1) relaxation time showed significant differences. The results obtained in phantom indicate that we can use this result for measurements of relaxation time in vitro. Conclusion. Infliximab is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. We conclude, that Quantitative Magnetic Resonance Imaging can be used to monitor drug effects.
The advancement of imaging in diagnosis of prostate cancer
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Osuchowski, Michał; Aebisher, David; Gustalik, Joanna; Bartusik-Aebisher, Dorota; Kaznowska, Ewa
Introduction. Multiple imaging methods have been used to stage prostate carcinoma. Some of them are easily accessible, others very accurate. The advancements over many years have been taken under consideration and now every imaging method has a specific role in the diagnosis of this malignancy. Aim. There are over 1,100,000 cases of prostate carcinoma diagnosed every year around the world. Imaging examinations have to be introduced to accurately stage, and therefore properly treat this disease. This review concentrates on advantages and disadvantages of different imaging methods. Material and methods. The literature search was performed. Results. Imaging methods serve specific goals. TRUS is recommended for acquiring biopsy specimen due to high accessibility and low cost of the examination. Conclusion. The best tool for staging prostate carcinoma and finding suspicious lesions when attempting second biopsy is mpMRI or bpMRI.

Przeglądaj

Przeglądanie European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019) według Autor "Aebisher, David"